ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
| Business Activity | PASS |
| Debt Ratio | N/A |
| Cash Ratio | N/A |
| Receivables Ratio | N/A |
| Revenue Ratio | N/A |
| Overall | INSUFFICIENT DATA |
$930.2M
3.77
1.523
12
$419.0K
1.00
17.18
0.2%
77
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($41.94, 12 analysts) | |||
| 10 | $274.70 | +$144.70 (53%) | 3.5R |
| 50 | $1,373.50 | +$723.50 (53%) | 3.5R |
| 100 | $2,747.00 | +$1,447.00 (53%) | 3.5R |
- High beta (1.52) — amplifies market moves by 1.52x
- Elevated short interest (17.18 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| DNLI | 0.440 |
| ARKG | 0.426 |
| HQH | 0.418 |
| SYRE | 0.409 |
| NUVL | 0.403 |
| Ticker | Correlation |
|---|---|
| ALEC.AE | -0.162 |
| PXED | -0.137 |
| ABC.BH | -0.130 |
| PANSAR.KL | -0.129 |
| RAKNIC.AB | -0.127 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.